LEADER 06237nam 22006975 450 001 9910842298503321 005 20251008154952.0 010 $a3-031-38605-1 024 7 $a10.1007/978-3-031-38605-3 035 $a(CKB)30597235700041 035 $a(MiAaPQ)EBC31201017 035 $a(Au-PeEL)EBL31201017 035 $a(DE-He213)978-3-031-38605-3 035 $a(OCoLC)1425792749 035 $a(EXLCZ)9930597235700041 100 $a20240229d2023 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPractical Management of Thyroid Cancer $eA Multidisciplinary Approach /$fedited by Ujjal K. Mallick, Clive Harmer 205 $a3rd ed. 2023. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2023. 215 $a1 online resource (393 pages) 225 1 $aMedicine Series 311 08$a3-031-38604-3 320 $aIncludes bibliographical references and index. 327 $a1. Pragmatism, Precision Oncology, International Partnership for Research and Quality-The New Paradigm for Thyroid Cancer -- Section I. Multidisciplinary Approach to Management of Thyroid Cancer -- 2. The UK Evidence-Based Guidelines for the Management of Thyroid Cancer: Key Recommendations -- 3. The 2015 American Thyroid Association Evidence-Based Guidelines for Management of Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Key Recommendations -- 4. Thyroid Cancer: One Doctor-Patient Partnership -The Newcastle Butterfly Model -- Section II. The Diagnosis of Thyroid Cancer -- 5. Molecular Diagnosis of Thyroid Nodules -- 6. Ultrasonography in Diagnosis and Management of Thyroid Cancer ?Current International Recommendations -- Section III. Initial Thyroid Surgery -- 7. The 21st Century Endocrine Surgeon -- 8. Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer -- 9. Advances in Thyroid Surgery -- Section IV. Non surgical Management ofDifferentiated Thyroid Cancer -- 10. Risk Stratification and Current Management of Low Risk Thyroid Cancer -- 11. Management of Low risk Papillary Thyroid Carcinomo and Papillary Cancer and Microcarcinoma-the Japanese experience -- 12. Radioiodine Ablation ? Current Status -- 13. Dosimetric Approaches ? Current Concepts -- 14. External Radiation in Differentiated Thyroid Cancer in the era of IMRT and modern radiation planning techniques -- Section V. Follow up and Longterm Management of Differentiated Thyroid Cancer -- 15. Thyroglobulin -- 16. Management of Post-Operative Hypocalcemia -- 17. Radioiodine Refractory Thyroid Cancer -- Section VI. Medullary Thyroid Carcinoma -- 18. Medullary Thyroid Cancer :Surgical Management -- 19. Medullary Thyroid Cancer: Diagnosis and Non Surgical Management -- 20. Familial Non-Medullary Thyroid Cancer -- Section VII. Thyroid Cancer in Children -- 21. Pediatric Differentiated Thyroid Carcinoma -- Section VIII. Aggressive ThyroidCancers -- 22. Anaplastic Thyroid Cancer -- 23. Palliative care -- Section IX. Future Developments and Directions for Research in Thyroid Cancer -- 24. Translational Research and Genomics Driven Trials in Thyroid Cancer -- 25. Thyroid Cancer Trials -- 26. The Barriers to Uniform Implementation of Clinical Practice Guidelines (CPG) for Thyroid Cancer -- 27. Survivorship: The Role of the Clinical Psychologist and the Clinical Nurse Specialist in Thyroid Cancer Care. 330 $aWritten by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer. It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic. The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRK gene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed. The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well. This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists. 410 0$aMedicine Series 606 $aOncology 606 $aSurgery 606 $aEndocrinology 606 $aPrimary care (Medicine) 606 $aPathology 606 $aOncology 606 $aSurgery 606 $aEndocrinology 606 $aPrimary Care Medicine 606 $aPathology 615 0$aOncology. 615 0$aSurgery. 615 0$aEndocrinology. 615 0$aPrimary care (Medicine) 615 0$aPathology. 615 14$aOncology. 615 24$aSurgery. 615 24$aEndocrinology. 615 24$aPrimary Care Medicine. 615 24$aPathology. 676 $a616.99444 702 $aMallick$b Ujjal K. 702 $aHarmer$b Clive 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910842298503321 996 $aPractical Management of Thyroid Cancer$94145608 997 $aUNINA